ATLANTA, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq: BOTA ) today announced that its President and Chief Executive Officer, Russell H. Plumb, will present an update on the company at the 26th Annual ROTH Conference at 12:30 p.m. PDT, March 11, 2014, at The Ritz-Carlton, Dana Point in California.
The presentation will be webcast live and may be accessed through the Investor Relations' Events and Presentations section on Biota's website at www.biotapharma.com . Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software. An archived replay will also be available for 90 days following the live presentation.
About Biota
Biota Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases. The Company currently has two Phase 2 clinical-stage product candidates in development: laninamivir octanoate, a long-acting neuraminidase inhibitor that the Company is developing for the treatment of influenza A and B infections under an investigational new drug application (IND) in the United States through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) that is designed to provide up to $231 million in financial support to complete its clinical development; and vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus (HRV). In addition to these clinical-stage programs, the Company has a preclinical program focused on developing treatments for respiratory syncytial virus (RSV). For additional information about the Company, please visit www.biotapharma.com .
Biota is a registered trademark of Biota Holdings Limited.
Russell H. Plumb President & CEO (678) 221-3351 Lee M. Stern The Trout Group